Mydrane

Lidocaine Hydrochloride, Phenylephrine Hydrochloride, Tropicamide, the active ingredient in Mydrane, is a local anesthetic; alpha‑adrenergic agonist; anticholinergic presented as an intracameral solution for intra‑ocular use. It provides rapid pupil dilation and anesthesia during cataract and other intra‑ocular surgeries. GNH USA supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mydrane acts on the ocular anterior segment to facilitate surgical procedures. - Cataract surgery: rapid pupil dilation and intra‑ocular anesthesia to enable safe lens removal. - Other intra‑ocular surgery: provides mydriasis and analgesia for procedures such as trabeculectomy or vitrectomy. - Anterior segment procedures: assists with anesthesia and dilation during corneal transplants and iridectomy.

Mydrane may cause ocular and systemic reactions after administration.

Common Side Effects: - Transient ocular pain or discomfort. - Temporary increase in intra‑ocular pressure. - Mild corneal edema or haze. - Slight anterior chamber inflammation. - Blurred vision lasting a few hours. - Headache or mild systemic flushing.

Serious or Rare Side Effects: - Allergic reaction with rash, itching, or anaphylaxis. - Persistent or uncontrolled mydriasis. - Severe hypotension or cardiovascular instability. - Retinal toxicity or vision loss. - Endophthalmitis or severe intra‑ocular infection. - Significant ocular inflammation requiring intervention.

Mydrane should be used with careful patient assessment and monitoring. - Allergy assessment: avoid in patients with known hypersensitivity to any component. - Intra‑ocular pressure: monitor before and after injection, especially in glaucoma patients. - Cardiovascular status: use cautiously in patients with uncontrolled hypertension or cardiac disease. - Ocular infection: contraindicated in active intra‑ocular infections. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at controlled room temperature: keep in original packaging, protect from light and moisture.

Mydrane may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent use of other potent mydriatics may cause excessive pupil dilation and iris ischemia. - Simultaneous administration of additional local anesthetics can increase risk of ocular toxicity.

Moderate Interactions (Monitor Closely): - Systemic alpha‑adrenergic agonists may augment cardiovascular effects of phenylephrine. - Anticholinergic drugs can potentiate tropicamide‑related systemic anticholinergic effects. - Beta‑blocker eye drops may blunt intra‑ocular pressure response. - NSAID eye drops may affect inflammation profile when used together.